MDS is a bone marrow disease that causes an increasing number of dysfunctional blood cells called blasts to develop from stem cells and proliferate in the blood stream at the expense of normal cells. As a result, fewer normal red blood cells will circulate to carry oxygen to cells resulting in anemia; fewer white blood cells will be available to fight infections; and fewer platelets to control bleeding. Although MDS has not been considered cancer in the past, most hematologists (specialists in diseases of the blood) now think it is a form of bone marrow cancer (i.e. leukemia).
MDS generally afflicts adults over 50 years old, and therapy is supportive rather than curative. However, a subset of MDS patients will develop blood cell cancer, or leukemia. These high-risk patients have been shown to benefit from a new DNA hypomethylating agent, decitabine, undergoing clinical trials. The results of these trials are revealed in a related article by Kantarjian et al. also published in the April 15, 2006 issue of CANCER.
Little is known about the optimal duration of treatment with decitabine and the effect of retreatment for relapse. Led by Michael Lbbert, M.D., Ph.D. of the University of Freiburg Medical Center in Freiburg, German
'"/>
Contact: David Greenberg
dgreenbe@wiley.com
201-748-6484
John Wiley & Sons, Inc.
13-Mar-2006